Participant ID:	CoVPN 5001	Visit Code:	

Form: Interim Visit

Interim visit code	
Date of visit	
What is/are the reason(s) for this interim visit?	
Mark all that apply.	
Participant missing part or all of a scheduled study visit and is outside of visit window.	
Participant contacted site to report updated Medical History.	
Update Medical History log.	
Participant contacted site to report updated Concomitant Medications.	
Update Concomitant Medication log.	
Repeat specimen collection	
Other reason	
If "Other reason", specify (max. 200 characters):	
Did the participant exit/terminate the study at this visit?	Yes
If "Yes", complete Termination form.	No
FORMS COMPLETED AT INTERIM VISIT:	
Hematology	
Participant Transfer	
Participant Receipt	
Pregnancy Test Results	
Specimen Collection - Blood	

This module contains Form "Interim Visit" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Response to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 14) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective Study of Acute Immune Responses to SARS COV-2 Infection" (page 15) from the full document "Prospective